These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 16676328

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mechanisms of Kappa Opioid Receptor Potentiation of Dopamine D2 Receptor Function in Quinpirole-Induced Locomotor Sensitization in Rats.
    Escobar AP, González MP, Meza RC, Noches V, Henny P, Gysling K, España RA, Fuentealba JA, Andrés ME.
    Int J Neuropsychopharmacol; 2017 Aug 01; 20(8):660-669. PubMed ID: 28531297
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reduced dopamine and glutamate neurotransmission in the nucleus accumbens of quinpirole-sensitized rats hints at inhibitory D2 autoreceptor function.
    Escobar AP, Cornejo FA, Olivares-Costa M, González M, Fuentealba JA, Gysling K, España RA, Andrés ME.
    J Neurochem; 2015 Sep 01; 134(6):1081-90. PubMed ID: 26112331
    [Abstract] [Full Text] [Related]

  • 11. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Sep 01; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 12. Behavioral sensitization to quinpirole is not associated with increased nucleus accumbens dopamine overflow.
    Koeltzow TE, Austin JD, Vezina P.
    Neuropharmacology; 2003 Jan 01; 44(1):102-10. PubMed ID: 12559127
    [Abstract] [Full Text] [Related]

  • 13. Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors.
    Izenwasser S, Acri JB, Kunko PM, Shippenberg T.
    Synapse; 1998 Nov 01; 30(3):275-83. PubMed ID: 9776131
    [Abstract] [Full Text] [Related]

  • 14. Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats.
    Perreault ML, Graham D, Scattolon S, Wang Y, Szechtman H, Foster JA.
    Psychopharmacology (Berl); 2007 Nov 01; 194(4):485-96. PubMed ID: 17619861
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Altered neurochemical and behavioral development of 10-day-old rats perinatally exposed to the kappa opioid agonist U-50,488H.
    Shieh GJ, Walters DE.
    Neurosci Lett; 1994 Jul 18; 176(1):37-40. PubMed ID: 7970232
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacological stimuli decreasing nucleus accumbens dopamine can act as positive reinforcers but have a low addictive potential.
    Marinelli M, Barrot M, Simon H, Oberlander C, Dekeyne A, Le Moal M, Piazza PV.
    Eur J Neurosci; 1998 Oct 18; 10(10):3269-75. PubMed ID: 9786220
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.